Concordance and generalization of an AI algorithm with real-world clinical data in the pre-omicron and omicron era

被引:0
|
作者
Yilmaz, Gulsen [1 ,2 ]
Sezer, Sevilay [2 ]
Bastug, Aliye [3 ]
Singh, Vivek [4 ]
Gopalan, Raj [5 ]
Aydos, Omer [6 ]
Ozturk, Busra Yuce [6 ]
Gokcinar, Derya [7 ]
Kamen, Ali [4 ]
Gramz, Jamie [5 ]
Bodur, Hurrem [3 ]
Akbiyik, Filiz [8 ]
机构
[1] Ankara Yildirim Beyazit Univ, Dept Med Biochem, Ankara, Turkiye
[2] Ankara Bilkent City Hosp, Dept Med Biochem, Minist Hlth, Ankara, Turkiye
[3] Hlth Sci Univ Turkey, Ankara City Hosp, Gulhane Med Sch, Dept Infect Dis & Clin Microbiol, Ankara, Turkiye
[4] Siemens Healthineers, Digital Technol & Innovat, Princeton, NJ USA
[5] Siemens Healthineers, Tarrytown, NY USA
[6] Ankara City Hosp, Dept Infect Dis & Clin Microbiol, Ankara, Turkiye
[7] Hlth Sci Univ Turkey, Ankara Bilkent City Hosp, Dept Anesthesiol & Reanimat, Ankara, Turkiye
[8] Siemens Healthineers, Ankara City Hosp Lab, Ankara, Turkiye
关键词
COVID-19; Algorithms; Predictive value of tests; Disease severity; Clinical laboratory tests;
D O I
10.1016/j.heliyon.2024.e25410
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
All viruses, including SARS-CoV-2, the virus responsible for COVID-19, continue to evolve, which can lead to new variants. The objective of this study is to assess the agreement between real -world clinical data and an algorithm that utilizes laboratory markers and age to predict the progression of disease severity in COVID-19 patients during the pre -Omicron and Omicron variant periods. The study evaluated the performance of a deep learning (DL) algorithm in predicting disease severity scores for COVID-19 patients using data from the USA, Spain, and Turkey (Ankara City Hospital (ACH) data set). The algorithm was developed and validated using pre -Omicron era data and was tested on both pre -Omicron and Omicron -era data. The predictions were compared to the actual clinical outcomes using a multidisciplinary approach. The concordance index values for all datasets ranged from 0.71 to 0.81. In the ACH cohort, a negative predictive value (NPV) of 0.78 or higher was observed for severe patients in both the pre -Omicron and Omicron eras, which is consistent with the algorithm's performance in the development cohort.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] The limits of fair medical imaging AI in real-world generalization
    Yang, Yuzhe
    Zhang, Haoran
    Gichoya, Judy W.
    Katabi, Dina
    Ghassemi, Marzyeh
    NATURE MEDICINE, 2024, 30 (10) : 2838 - 2848
  • [22] Harnessing oncology real-world data with AI
    Piers Mahon
    Geoff Hall
    Andre Dekker
    Janne Vehreschild
    Giovanni Tonon
    Nature Cancer, 2023, 4 : 1627 - 1629
  • [23] Harnessing oncology real-world data with AI
    Mahon, Piers
    Hall, Geoff
    Dekker, Andre
    Vehreschild, Janne
    Tonon, Giovanni
    NATURE CANCER, 2023, 4 (12) : 1627 - 1629
  • [24] Examining Endpoint Concordance in Clinical Trials and Real-World Clinical Practice to Advance Real-World Evidence Utilization
    Schaumberg, Debra
    Larholt, Kay
    Apgar, Elizabeth
    Pashos, Chris L.
    Hirsch, Gigi
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2023, 57 (03) : 472 - 475
  • [25] Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel
    Weil, Clara
    Bergroth, Tobias
    Eisenberg, Anna
    Whiteside, Yohance Omar
    Caraco, Yoseph
    Tene, Lilac
    Chodick, Gabriel
    EPIDEMIOLOGIA, 2023, 4 (03): : 309 - 321
  • [26] Examining Endpoint Concordance in Clinical Trials and Real-World Clinical Practice to Advance Real-World Evidence Utilization
    Debra Schaumberg
    Kay Larholt
    Elizabeth Apgar
    Chris L. Pashos
    Gigi Hirsch
    Therapeutic Innovation & Regulatory Science, 2023, 57 : 472 - 475
  • [27] Fighting Omicron epidemic in China: Real-world big data from Fangcang shelter hospital during the outbreak in Shanghai
    Ye, Lingying
    Li, Wing Fai
    Shao, Jinsong
    Xu, Zhengmei
    Ju, Jintao
    Xu, Huji
    JOURNAL OF INFECTION, 2022, 85 (04) : 451 - 453
  • [28] Real-world clinical outcomes of tixagevimab/cilgavimab in the Omicron outbreak in China: baseline characteristics and interim analysis of the CLEAR study
    You, Jianhua
    Wu, Haidi
    Tian, Jiaxin
    Wen, Jianru
    Shi, Wenbo
    Wang, Zhi
    Du, Yanjun
    Xu, Hongwei
    Wei, Hanyu
    Li, Xiang
    Kang, Wenyan
    Zhou, Min
    Gu, Zhidong
    Qu, Jieming
    VIROLOGY JOURNAL, 2024, 21 (01)
  • [29] COVID-19 fatality and DALYs, and associated metabolic disorders and ambient air pollutants in pre-Omicron era of the pandemic: an international comparative study
    Ngatu, Nlandu-Roger
    Tonduangu, Daniel-Kuezina
    Munyeshyaka, Emmanuel
    Hirao, Tomohiro
    Balenda, Georges-Matondo
    Yamadori, Yusuke
    Deguchi, Takayuki
    Nsadi-Fwene, Berthier
    Lami, Jose-Nzunzu
    Akumwami, Steeve
    Kanda, Kanae
    Murakami, Akitsu
    Yandju, Marie -Claire
    Nyembue, Dieudonne-Tshipukane
    Tshimpi, Antoine
    Wembonyama, Stanislas-Okitotsho
    ENVIRONMENTAL HEALTH AND PREVENTIVE MEDICINE, 2024, 29
  • [30] Real-World or Controlled Clinical Trial Data in Real-World Practice
    Wu, Ting-Hui
    Yang, James Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : 470 - 472